Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Simone Scagnoli
Observed name:
S. Scagnoli
Institution:
Sapienza University of Rome
Observed institutions:
Policlinico Umberto I,
Sapienza University of Rome
ORCID:
0000-0003-4943-5622
Observed ORCID:
0000-0003-4943-5622
OpenAlex ID:
A5066168416
LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy
2024
·
A. Botticelli
, S. Scagnoli
, et al.
·
Annals of Oncology
·
25
70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial
2023
·
A. Botticelli
, S. Scagnoli
, et al.
·
ESMO Open
·
4
PDF
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors
2026
·
Roberta Scafetta
, Raffaella Troiano
, et al.
·
European Journal of Cancer
·
1
PDF
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases
2026
·
Roberta Scafetta
, Marco Donato
, et al.
·
The Oncologist
·
1
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study
2026
·
Roberta Scafetta
, Raffaella Troiano
, et al.
·
European Journal of Cancer
·
1
14P Comprehensive genomic profiling to guide personalized targeted and immunotherapy in gastrointestinal tumors: Subgroup analysis of the ROME trial
2025
·
C. Cremolini
, A. Botticelli
, et al.
·
Annals of Oncology
·
1
206P Genomic and Immune profiling in early-stage HR+ breast cancer: Correlation between recurrence score and PD-L1 expression
2025
·
S. Pisegna
, S. Scagnoli
, et al.
·
ESMO Open
·
1
PDF
606P Reproductive system disorders during targeted therapies for breast cancer: A pharmacovigilance analysis
2026
·
G. Gentile
, L. Arecco
, et al.
·
ESMO Open
PDF
472P Cumulative incidence of trastuzumab-deruxtecan–related interstitial lung disease in a multicenter real-world cohort
2026
·
C. Gullotta
, R. Scafetta
, et al.
·
ESMO Open
Renal Involvement in Cancer Patients Undergoing Oncology Therapies: Implications for Personalized Treatment Strategies
2026
·
Silvia Lai
, Alessandra Punzo
, et al.
·
Journal of Personalized Medicine
PDF
188P Sacituzumab govitecan after immune checkpoint inhibitors in metastatic TNBC: Real-world evidence
2025
·
M. Piezzo
, R. Caputo
, et al.
·
Immuno-Oncology Technology
PDF
139P ROME Trial: Predictive value of TMB cutoffs, concordance, and treatment line in immunotherapy for hTMB/MSS cancers
2025
·
A. Botticelli
, S. Scagnoli
, et al.
·
Annals of Oncology
95O Atezolizumab plus ipatasertib shows promise in extending survival for patients with PI3K/AKT/PTEN-altered advanced solid tumors: An exploratory analysis of the ROME trial
2025
·
A. Botticelli
, S. Lonardi
, et al.
·
ESMO Open
Show more works
View as search
Works count:
13
Citation count:
34
H-index:
2
I10-index:
1
Year
Topic
Type